Upcoming Events
  1. 4th ALTG Preceptorship in Lung Cancer, Melbourne, VIC

    August 17 - August 18

ALTG 11/002 Temozolomide and PARPI as 2LC for SCLC

Phase I/II study of temozolomide and PARP (Poly ADP ribose polymerase) inhibitor as a second line chemotherapy for SCLC. This study concept is on hold and will be reviewed once the results of an ongoing Phase 1 study at UCLA exploring the combination are available.

Any further enquiries regarding this trial should be directed to the CTC Clinical Lead A/Prof Martin Stockler, atmartin.stockler@sydney.edu.au